Engerix-B Vaccine Induced Transient Hepatitis B Surface Antigenemia: A Case Report and Review of the Literature

Sam,; Aadn, ika Saparamadu; Lee, Joanne; Tt, Lui; Lam, Choong Weng

doi:10.21767/2471-8505.100124

J Intensive & Crit Care

2019

DOI: 10.21767/2471-8505.100124

|View full text |Cite

Engerix-B Vaccine Induced Transient Hepatitis B Surface Antigenemia: A Case Report and Review of the Literature

Sam Sam¹,

ika Saparamadu Aadn²,

Joanne Lee³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Earlier studies in various populations, ranging from infants and adults to healthy blood donors and patients undergoing hemodialysis, have revealed a transient hepatitis B surface antigenemia after patients have received immunization with the older 2 vaccines, which resolved at 3 weeks' follow-up. [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] We hypothesize that a similar phenomenon may be observed with Heplisav-B administration.…”

mentioning

confidence: 94%

Transient Hepatitis B Surface Antigenemia Following Immunization with Heplisav-B

Campioli

Garrigos

Assi

et al. 2021

Mayo Clinic Proceedings: Innovations, Quality & Outcomes

View full text Add to dashboard Cite

Objective: To delineate the rate and duration of transient hepatitis B surface antigenemia following Heplisav-B vaccination. Patients and Methods: We retrospectively reviewed the medical records of all adult patients who received Heplisav-B vaccination at our institution from January 1, 2019, through March 31, 2020, and who had hepatitis B surface antigen (HBsAg) testing within 30 days following immunization. Patients with laboratory evidence of prior hepatitis B virus infection or immunization were excluded. Results: A total of 39 of 1933 patients were tested for HBsAg within 30 days after completing the Heplisav-B vaccination series; of these 39, only 6 (15.4 %) had a positive HBsAg result. Compared with the patients with negative HBsAg results, those with a positive HBsAg result had a significantly lower body mass index (24.8 kg/m 2 [interquartile range (IQR), 23 to 26.4 kg/m 2 ] vs 28.6 kg/m 2 [IQR, 26.4 to 30.6 kg/m 2 ]; P¼.01) and higher prevalence of chronic kidney disease (2 of 6 [33.3%] vs 2 of 33 [6%]; P¼.04). The timing of HBsAg testing after completing the vaccination series in the HBsAg-positive group was significantly earlier compared with that of the HBsAg-negative group (2 days [IQR, 0.43 to 2.25 days) vs 12 days [IQR, 10 to 15 days]; P¼.0008). Active hepatitis B infection was excluded in all 6 patients. In the HBsAg-positive group, the median time from the date of Heplisav-B administration to a negative HBsAg test result was 17 days (IQR, 8 to 36 days). Conclusion:As with all conventional hepatitis B vaccines, transient hepatitis B surface antigenemia can be observed with Heplisav-B vaccine, particularly in those with chronic kidney disease and low body mass index.

show abstract

mentioning

confidence: 94%

Transient Hepatitis B Surface Antigenemia Following Immunization with Heplisav-B

Campioli

Garrigos

Assi

et al. 2021

Mayo Clinic Proceedings: Innovations, Quality & Outcomes

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Engerix-B Vaccine Induced Transient Hepatitis B Surface Antigenemia: A Case Report and Review of the Literature

Cited by 1 publication

References 30 publications

Transient Hepatitis B Surface Antigenemia Following Immunization with Heplisav-B

Transient Hepatitis B Surface Antigenemia Following Immunization with Heplisav-B

Contact Info

Product

Resources

About